Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. (NASDAQ: CERT) is a software‑driven company in the model‑informed drug development and biosimulation space. The CERT news page on Stock Titan aggregates company‑specific headlines so readers can follow how Certara’s biosimulation software, technology, and services are discussed in earnings releases, product announcements, scientific updates, and corporate events.
Recent Certara news highlights several recurring themes. The company issues quarterly financial results that describe revenue from biosimulation software and services, bookings trends, and updates to its full‑year financial outlook. These results are typically accompanied by commentary on demand for model‑informed drug development solutions and the performance of its software and services portfolio.
Certara also regularly announces new software capabilities and platform enhancements. Examples in recent releases include the launch of Certara IQ, an AI‑powered quantitative systems pharmacology solution, and TFL Studio, the first cloud‑native module of its Phoenix Cloud platform for pharmacokinetic and pharmacodynamic workflows. The company has additionally introduced Pinnacle 21 Enterprise Plus for managing CDISC SDTM and ADaM data specifications used in regulatory submissions.
Another category of news involves scientific recognition and research output, such as announcements about Certara scientists being listed among highly cited researchers and the publication of hundreds of scientific papers in a year. Corporate governance and leadership updates, including changes in the chief executive officer role, appear in both press releases and related SEC filings.
Investors, analysts, and industry professionals can use this news feed to monitor Certara’s financial disclosures, product roadmap, scientific contributions, and capital markets activity over time.
Certara (Nasdaq: CERT) said its Simcyp Simulator PBPK modeling was accepted by the U.S. FDA in lieu of clinical studies to support the NDA for asciminib (Scemblix) for chronic myeloid leukemia. The modeling reportedly replaced at least ten dedicated clinical pharmacology studies and characterized asciminib pharmacokinetics across healthy volunteers and cancer patients.
The simulations bridged tested and untested scenarios, assessed drug–drug interactions, and supported dosing-regimen evaluation, reflecting a decade-long modeling effort and regulatory acceptance that reduced clinical study needs and development time.
Certara (Nasdaq: CERT) said management will participate in three investor conferences in early March 2026: TD Cowen on March 3 at 3:10PM ET, Leerink Global Healthcare on March 9 at 8:00AM ET, and Barclays Global Healthcare on March 10 at 1:00PM ET.
Live webcasts will be available on Certara’s investor relations website and replays will be accessible for at least 90 days.
Certara (Nasdaq: CERT) reported FY2025 revenue of $418.8M (9% growth) and adjusted EBITDA of $134.5M (10% growth). Q4 2025 revenue was $103.6M (+3%) with adjusted EBITDA of $32.5M (down 3%) and a Q4 net loss of $5.9M. Management named Jon Resnick CEO effective Jan 1, 2026. For full-year 2026 the company guides revenue growth of 0–4%, adjusted EBITDA margin of 30–32%, adjusted diluted EPS of $0.44–$0.48, and fully diluted shares of 160–162M.
Q4 bookings were $155.2M (+7%) including services bookings of $99.1M (+17%). The company cited higher operating expenses in Q4 driven by employee costs and refinancing-related transaction expenses.
Certara (NASDAQ:CERT) will release fourth quarter and full year 2025 financial results before market open on February 26, 2026. Management will host a conference call to discuss results at 8:30 AM ET. Investors must register online and are advised to register at least one day early. A live and archived webcast will be available in the Investors section of Certara's website.
Certara (Nasdaq: CERT) appointed Jon Resnick as Chief Executive Officer and board member effective January 1, 2026, succeeding William F. Feehery, who will step down as CEO on December 31, 2025 and serve as an external advisor during the transition. Resnick brings over 20 years of life‑sciences leadership at IQVIA, including service as President of the U.S. and Canada region since 2019.
The board thanked Feehery for guiding Certara through its IPO and software investments. The company also reaffirmed its full‑year 2025 financial outlook as previously disclosed on November 6, 2025.
Certara (Nasdaq: CERT) reported third quarter 2025 results: revenue $104.6M (+10% YoY), software revenue $43.8M (+22% YoY; organic software +6%), and services revenue $60.8M (+3% YoY). Net income was $1.5M versus a $1.4M loss a year earlier; diluted EPS was $0.01. Adjusted EBITDA was $35.2M (+7% YoY) and adjusted net income was $22.2M (+$2.0M YoY). Bookings totaled $96.6M (+1% YoY) with software bookings $40.8M (+17%) and services bookings $55.8M (−9%).
The company narrowed and raised full-year 2025 guidance to $415M–$420M revenue, target ~32% adjusted EBITDA margin, and $0.45–$0.47 adjusted diluted EPS with fully diluted shares of 160M–162M.
Certara (NASDAQ: CERT) launched TFL Studio, the first cloud-native module of its Phoenix Cloud platform, on November 4, 2025. TFL Studio is a no-code environment for creating tables, figures, and listings (TFLs) used in regulatory submissions and publications, and it integrates with Integral, Certara’s data repository.
Certara says TFL Studio can deliver TFLs up to 50% faster. A complementary module, AI PK Reports powered by CoAuthor, will be released this quarter and aims to cut PK report drafting from days to minutes.
Certara (Nasdaq: CERT) said company management will participate in three investor conferences in November 2025 and that live webcasts and replays will be available on the company investor relations website.
- UBS Global Healthcare Conference — Tuesday, November 11, 2025 at 2:00 PM ET
- Jefferies Global Healthcare Conference (London) — Tuesday, November 18, 2025 at 10:30 AM GMT
- Stephens Annual Investment Conference — Tuesday, November 18, 2025 at 1:00 PM CT
Live webcasts will stream at https://ir.certara.com and replays will be available for at least 90 days after each event.
Certara (Nasdaq: CERT) launched Certara IQ on October 30, 2025, an AI-powered Quantitative Systems Pharmacology (QSP) platform designed to scale biosimulation across drug discovery and development.
The platform combines generative-AI, a library of pre-built scientifically validated QSP models and templates, a no-code “what-if” interface, and a high-performance simulation engine that the company says runs simulations thousands of times faster than traditional tools.
Certara IQ aims to improve model reproducibility, reduce manual work, shorten simulation times, and support dosing and patient-population decision making.
Certara (Nasdaq: CERT) highlighted scientific impact on Oct 20, 2025 after publishing >200 papers in the past year and placing 11 Certara scientists on the 2025 Stanford/Elsevier top 2% most‑cited researchers list.
The release notes the company’s longstanding leadership in pharmacology and pharmacokinetics, the Simcyp Simulator’s use by more than 11 global regulatory agencies and support for over 120 FDA‑approved drugs, the Simcyp Consortium’s 35 member companies, and recognition of Amin Rostami‑Hodjegan with the 2025 Lewis B. Sheiner Lecturer Award.